TISSUE REPAIR

ASX Announcement

10 September 2026

TRP Appointment of Chief Financial Officer (CFO)

Tissue Repair Limited (ASX:TRP) ("**TRP**" or the "**Company**") announces the appointment of Mr. Mark Bouw to the role of Chief Financial Officer of the Company effective today.

Mr Mark Bouw – Chief Financial Officer (fractional)

MBA, BSN, FAICD, MIPA AFA

Mr Bouw is the Founder and Chief Executive Officer of Straterra Australia, a specialist operating-partner and finance advisory firm for medtech, digital health and life sciences companies, and brings more than 30 years of experience across clinical practice, senior finance leadership and company directorship, including as an Independent Non-Executive Director of ASX-listed Volpara Health Technologies from January 2023 until its acquisition by Lunit in May 2024 (Straterra; Volpara 2023 Notice of Meeting). He has supported life sciences companies through exits to Conmed, Isto Biologics and Lunit representing more than US$443 million in combined transaction value, and has delivered over A$200 million in non-dilutive funding outcomes across the health and medtech sectors.

TRP's CEO, Tony Charara said he was pleased to welcome Mr. Bouw as a CFO of the Company.

The Company further advises that Mr Bouw will replace Mr Cohen as CFO, with effect from 10 September 2026. The Board wishes to thank Mr Dion Cohen for his services to the Company.

For further information in relation to this release please contact Sushma Kejriwal at s.kejriwal@acclime.com.

This announcement has been approved for release by TRP's board.

-ENDS-

About Tissue Repair

Tissue Repair Limited (ASX:TRP) is a Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987®, with a secondary focus on commercialising TR Pro+® a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures, as well as other acute wound products in its pipeline. The Company's longer-term strategy is to commercialise its propriety Glucoprime® API to treat a variety of wounds and skin conditions.